PD-Rx Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Revenue	18.35	18.95	21.27	28.72	21.6
Revenue Growth (YoY)	-3.16%	-10.93%	-25.92%	32.93%	2.74%
Cost of Revenue	12.92	13.32	14.56	17.65	14.65
Gross Profit	5.43	5.62	6.71	11.06	6.96
Selling, General & Admin	5.91	6.58	6.9	7.06	6.08
Operating Expenses	5.91	6.58	6.9	7.06	6.08
Operating Income	-0.48	-0.95	-0.19	4	0.88
Interest & Investment Income	0.19	0.23	0.06	0.02	0.01
EBT Excluding Unusual Items	-0.29	-0.73	-0.13	4.02	0.89
Gain (Loss) on Sale of Assets	0.01	0.01	0	0.03	0.01
Other Unusual Items	-	-	-	-	0.93
Pretax Income	-0.28	-0.71	-0.13	4.05	1.83
Income Tax Expense	-0.02	0.04	-0.03	1.02	-0.02
Net Income	-0.26	-0.75	-0.1	3.03	1.86
Net Income to Common	-0.26	-0.75	-0.1	3.03	1.86
Net Income Growth	-	-	-	63.44%	-
Shares Outstanding (Basic)	2	2	2	2	2
Shares Outstanding (Diluted)	2	2	2	2	2
Shares Change (YoY)	-1.74%	0.22%	-1.42%	-3.54%	-1.56%
EPS (Basic)	-0.16	-0.46	-0.06	1.83	1.08
EPS (Diluted)	-0.16	-0.46	-0.06	1.83	1.08
EPS Growth	-	-	-	69.44%	-
Free Cash Flow	0.76	-1.43	1.36	2.69	-0.57
Free Cash Flow Per Share	0.47	-0.87	0.83	1.62	-0.33
Gross Margin	29.61%	29.68%	31.56%	38.52%	32.20%
Operating Margin	-2.60%	-5.03%	-0.90%	13.94%	4.06%
Profit Margin	-1.40%	-3.98%	-0.46%	10.57%	8.59%
Free Cash Flow Margin	4.16%	-7.54%	6.40%	9.35%	-2.66%
EBITDA	-0.33	-0.8	-0.05	4.13	0.99
EBITDA Margin	-1.79%	-4.22%	-0.24%	14.39%	4.59%
D&A For EBITDA	0.15	0.15	0.14	0.13	0.11
EBIT	-0.48	-0.95	-0.19	4	0.88
EBIT Margin	-2.60%	-5.03%	-0.90%	13.94%	4.06%
Effective Tax Rate	-	-	-	25.14%	-
Advertising Expenses	0.06	0.1	0.06	0.05	0.03